News | July 01, 2022
Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Cantourage introduces second Clever Leaves medical cannabis product to the German market
New Director supports NASDAQ rule on diversity
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Subscribe To Our Newsletter & Stay Updated
